Tourmaline Oil Corp. closed 7.6% below its 52-week high of C$70.83, which the company reached on February 21st.

Cash, cash equivalents and investments were $294.9 million as of December 31, 2024, as compared to $203.0 million as of December 31, 2023.

Tourmaline Oil Corp. closed 6.2% below its 52-week high of C$70.83, which the company achieved on February 21st.

Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total ...

Analysts at Wedbush issued their FY2024 EPS estimates for shares of Tourmaline Bio in a research note issued on Thursday, March 6th. Wedbush analyst L. Chico expects that the company will post ...

Fintel reports that on March 6, 2025, Wedbush initiated coverage of Tourmaline Bio (NasdaqGS:TRML) with a Outperform ...

Readers hoping to buy Tourmaline Oil Corp. ( TSE:TOU ) for its dividend will need to make their move shortly, as ...

Lifesci Capital issued their FY2024 earnings estimates for Tourmaline Bio in a research report issued on Monday, February 24th. Lifesci Capital analyst R. Katkhuda forecasts that the company will post ...

They're everywhere. For every 10,000 of them mined, only one Paraiba Tourmaline is discovered. But isn't luxury measured by rarity? Imagine a gem so incredibly rare it practically glows from ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

As of March 4, 2025, the average one-year price target for Tourmaline Bio is $58.43/share. The forecasts range from a low of $49.49 to a high of $77.70. The average price target represents an ...